Selinexor with BEAM before stem cell transplant for DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests adding selinexor to a standard chemotherapy regimen (BEAM) before a stem cell transplant for people with a certain type of large B-cell lymphoma that has MYC positive. It aims to see if this combination can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse large B-cell lymphoma that is MYC positive.
- You have had at least two prior treatments and your disease is in complete or partial remission.
- You are between 18 and 65 years old.
- You are healthy enough for a stem cell transplant (adequate organ function and performance status).
- You have not had a prior stem cell transplant or treatment with selinexor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding selinexor to the standard R-CHOP chemotherapy for people with a specific type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this combination works better as the first treatment.
This trial tests adding zanubrutinib to standard high-dose chemotherapy (BEAM) before a stem cell transplant for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if this combination helps control the lymphoma better before the transplant.
This trial is testing a new treatment for people with a type of lymphoma (DLBCL) that has not gone away or has come back. It combines a study drug called pirtobrutinib with a common chemotherapy regimen (BEAM) before a stem cell transplant, and the goal is to see if this approach is safe and effective in helping patients get to transplant.
This Phase 2 trial studies selinexor added to standard R-CHOP chemotherapy in people with a high-risk type of diffuse large B-cell lymphoma (DLBCL) that is “germinal center B-cell” (GC). It aims to improve disease control in people who need stronger treatment at the start.
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
This trial combines glofitamab and selinexor to treat diffuse large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if this two-drug combination works better than standard options.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.